Mylan on March 22 announced a recall of about 81,000 EpiPens distributed in Australia, New Zealand, Europe and Japan after two separate reports of the device failing to work properly during an emergency.
The recall now includes 13 lots of EpiPens distributed by Mylan between December 2015 and July 2016 to the U.S., along with additional markets in Asia, Europe and North and South America, according to the report.
The EpiPens may contain a defective part that prevents them from properly deploying, according to a Food and Drug Administration release.
More articles on supply chain:
Setting lower list prices — a first for pharma?
Swiss hospitals to transport lab samples via drone
4 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
